Lupin launches Rocuronium Bromide Injection in United States

08 Nov 2023 Evaluate

Lupin has launched Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials, after Lupin’s alliance partner Caplin Steriles (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (USFDA). 

Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials is the generic version of Zemuron Injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA Inc and is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection (RLD: Zemuron) had estimated annual sales of $54 million in the U.S. (IQVIA MAT August 2023). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2136.45 -0.70 (-0.03%)
27-Jan-2026 13:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1633.00
Dr. Reddys Lab 1240.00
Cipla 1316.15
Zydus Lifesciences 889.75
Lupin 2136.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×